IL1A and COVID-19: These observations led us to propose a two-step strategy for managing patients with COVID-19, which used elevated suPAR levels to first identify patients at risk of progressing to severe respiratory failure or death and then to initiate early targeted treatment with anakinra, a recombinant IL-1 receptor antagonist that blocks the activity of both IL-1α and IL-1β.